DAYLEIGH WISENER: Open Payments
NPI 1124710959 · ARAB, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$826 in 45 payments from 20 companies in 2025. Trend: 2023 $454 · 2024 $745 · 2025 $826
Food & beverage: $826
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $158 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $120 |
| PFIZER INC. | 4 | $79 |
| AstraZeneca Pharmaceuticals LP | 4 | $76 |
| SANOFI-AVENTIS U.S. LLC | 2 | $48 |
| Amgen Inc. | 3 | $44 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| Lilly USA, LLC | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
Products named: CAPLYTA, Kerendia, FARXIGA, TZIELD, OTEZLA, FANAPT, ELIQUIS, XIFAXAN.
Industry payments across AL — which companies pay providers there.
